Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes Roche returns to Innovent Biologics with new $1B biobucks ADC drug deal BeiGene, Brii and Ideaya ring in 2025 with deal news, betting billions in biobucks on prospects Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs Neumora stumbles at start of phase 3 depression readout run, sending stock down 80% Valo Health abandons ROCK inhibitor after phase 2 diabetic retinopathy fail CARsgen touts phase 2 stomach cancer win for cell therapy, revs up for China submission 2024 drug approvals: Small companies loom large with several key FDA nods | 